TOI (The Oncology Institute) ROCE %: -2.45% (As of Mar. 2026)


TOI The Oncology Institute Inc TOI
56 GF Score
Price $5.11
GF Value $2.24
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute ROCE %?

The Oncology Institute TOI -2.66% 56 ROCE % is -2.45% as of Mar. 2026. GuruFocus rates TOI with a GF Score™ of 56/100 and a GF Value™ of $2.24 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. The Oncology Institute's annualized ROCE % for the quarter that ended in Mar. 2026 was -2.45%.

The Oncology Institute  (NAS:TOI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

The Oncology Institute ROCE % Related Terms

The Oncology Institute ROCE % Historical Data

* Premium members only.

The historical data trend for The Oncology Institute's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Oncology Institute ROCE % Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -10.70 1.97 -37.56 -38.76 -46.18

The Oncology Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.84 -61.24 -60.43 -23.33 -2.45
TOI
56GF Score
The Oncology Institute Inc TOI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Oncology Institute ROCE % Calculation

The Oncology Institute's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-49.461/( ( (172.717 - 52.215) + (164.656 - 70.962) )/ 2 )
=-49.461/( (120.502+93.694)/ 2 )
=-49.461/107.098
=-46.18 %

The Oncology Institute's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-2.232/( ( (164.656 - 70.962) + (168.23 - 79.351) )/ 2 )
=-2.232/( ( 93.694 + 88.879 )/ 2 )
=-2.232/91.2865
=-2.45 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -2.45% mean?
The Oncology Institute (TOI) has a ROCE % of -2.45% as of Mar. 2026.
Is The Oncology Institute's ROCE % too high?
The Oncology Institute's current ROCE % is -2.45%. Overall, The Oncology Institute has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's ROCE % compare to CCRN and SRTA?
The Oncology Institute's ROCE % of -2.45% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current ROCE % is -2.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
Based on GuruFocus' analysis, The Oncology Institute (TOI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.24, compared to a current price of $5.11 — trading 127.9% above its estimated fair value. The current ROCE % is -2.45%. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For The Oncology Institute (TOI), the current ROCE % is -2.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The Oncology Institute (TOI) Overvalued in 2026?

Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued. The current stock price of $5.11 is trading 127.9% above its estimated GF Value™ of $2.24. GuruFocus considers The Oncology Institute to be Significantly Overvalued.

Key valuation signals for TOI:

  • ROCE %: -2.45%
  • GF Value™: $2.24 vs. price of $5.11 (127.9% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The Oncology Institute Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.11
Price
$2.24
GF Value